''GAS6/AXL PATHWAY IS ACTIVATED IN CHRONIC LIVER DISEASE AND ITS TARGETING REDUCES FIBROSIS VIA HEPATIC STELLATE CELL INACTIVATION.''

''GAS6/AXL PATHWAY IS ACTIVATED IN CHRONIC LIVER DISEASE AND ITS TARGETING REDUCES FIBROSIS VIA HEPATIC STELLATE CELL INACTIVATION.''

BÁRCENA C, STEFANOVIC M, TUTUSAUS A, JOANNAS L, MENÉNDEZ A, GARCÍA-RUIZ C, SANCHO-BRU P, MARÍ M, CABALLERIA J, ROTHLIN CV, FERNÁNDEZ-CHECA JC, GARCÍA DE FRUTOS P, MORALES A.,
2015
References: 
J Hepatol. 2015 Apr 20. pii: S0168-8278(15)00296-2. doi: 10.1016/j.jhep.2015.04.013